Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6818-0.0489 (-6.69%)
At close: 04:00PM EST
0.6698 -0.01 (-1.76%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7307
Open0.7300
Bid0.6860 x 1200
Ask0.6699 x 900
Day's Range0.6615 - 0.7399
52 Week Range0.4700 - 2.3400
Volume2,161,616
Avg. Volume6,131,792
Market Cap101.51M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.6370
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™

    Drug overdoses are the leading cause of death for those under age 50SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. The model data supports the dose of naloxone in ZIMHI as being more likely to produce successful resuscitation of high

  • GlobeNewswire

    Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

    SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) notifying the company that based on the company’s filing of its Quarterly Reports on Form 10-Q for the periods ended March 31,

  • GlobeNewswire

    Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update

    Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ETSAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine months ended September 30, 2021 and provided a business update. “Adamis made significant advancements over the past year,” stated Dennis J

Advertisement
Advertisement